Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALNY
  • CUSIP: 02043Q10
  • Web:
  • Market Cap: $7.07 billion
  • Outstanding Shares: 86,190,000
Average Prices:
  • 50 Day Moving Avg: $78.15
  • 200 Day Moving Avg: $57.51
  • 52 Week Range: $31.38 - $86.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.54
  • P/E Growth: -0.33
Sales & Book Value:
  • Annual Revenue: $58.77 million
  • Price / Sales: 120.29
  • Book Value: $9.65 per share
  • Price / Book: 8.50
  • EBIDTA: ($407,540,000.00)
  • Net Margins: -705.11%
  • Return on Equity: -42.90%
  • Return on Assets: -32.56%
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 6.23%
  • Quick Ratio: 6.23%
  • Average Volume: 1.08 million shs.
  • Beta: 2.98
  • Short Ratio: 6.48

Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Friday, May, 5th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million for the quarter, compared to analysts' expectations of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm's revenue for the quarter was up 160.3% on a year-over-year basis. During the same quarter last year, the company earned ($1.21) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When will Alnylam Pharmaceuticals make its next earnings announcement?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Alnylam Pharmaceuticals.

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?

17 equities research analysts have issued 1 year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $36.00 to $131.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $80.12 in the next year. View Analyst Ratings for Alnylam Pharmaceuticals.

What are analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)
  • 2. Needham & Company LLC analysts commented, "Alnylam reported additional results from Phase 2 OLE trial of fitusiran in Hemophilia A and B pts w/ and w/ o inhibitors. Efficacy w/ respect to Annualized Bleeding Rate and target antithrombin knockdown remains favorable and consistent w/ prior data from this program. Alnylam reported several asymptomatic >3X ALT elevations, one of which led to a discontinuation. Mgmt believes these events may be tied to HCV infection, highlighting that all events occurred in pts w/ history of HCV and most significant events were observed in pts w/ active infection. Alnylam is excluding Hemophilia pts w/ active HCV infection from Phase 3 trials. Data from Phase 1 trial published today are not consistent with a dose-dependent impact on ALT elevation. We continue to have a favorable view towards the program given current overall profile (safety, efficacy, and convenience), but acknowledge a level of risk around liver enzymes, which will probably not be clarified until Phase 3 completed." (7/10/2017)
  • 3. Chardan Capital analysts commented, "We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space." (11/30/2016)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:

  • Michael W. Bonney, Independent Chairman of the Board
  • Barry E. Greene, President
  • John M. Maraganore Ph.D., Chief Executive Officer, Director
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada
  • Peter F. Smith Ph.D., Senior Vice President - Early Development

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Rockefeller Financial Services Inc. (0.39%), Peregrine Capital Management LLC (0.23%), Aperio Group LLC (0.02%), Bank of Montreal Can (0.01%), Nisa Investment Advisors LLC (0.01%) and NN Investment Partners Holdings N.V. (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rockefeller Financial Services Inc., Peregrine Capital Management LLC and Winslow Evans & Crocker Inc.. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Hemenway Trust Co LLC, Capstone Asset Management Co., Nisa Investment Advisors LLC, Aperio Group LLC and Bank of Montreal Can. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $82.02.

MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  591 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  782
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $80.12 (2.32% downside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy -> Buy$80.00 -> $90.00LowView Rating Details
7/11/2017Cowen and CompanyReiterated RatingBuy$100.00LowView Rating Details
7/11/2017Credit Suisse GroupSet Price TargetBuy$96.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
7/10/2017Needham & Company LLCReiterated RatingBuy$98.00LowView Rating Details
7/10/2017Chardan CapitalReiterated RatingBuy$110.00 -> $131.00HighView Rating Details
6/26/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$102.00LowView Rating Details
6/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$116.00 -> $126.00LowView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform -> Sell$69.70 -> $67.00LowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$44.00 -> $64.00MediumView Rating Details
5/17/2017Leerink SwannReiterated RatingMarket Perform$53.00 -> $67.00HighView Rating Details
4/17/2017BMO Capital MarketsInitiated CoverageOutperform$73.00MediumView Rating Details
3/20/2017FBR & CoReiterated RatingBuyHighView Rating Details
2/3/2017JMP SecuritiesSet Price TargetBuy$69.00N/AView Rating Details
11/3/2016Barclays PLCReiterated RatingHold$50.00N/AView Rating Details
10/6/2016Stifel NicolausLower Price TargetHold$68.00 -> $36.00N/AView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($1.21)N/AView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
2017 EPS Consensus Estimate: ($5.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.30)($1.33)
Q2 20172($1.30)($1.20)($1.25)
Q3 20172($1.25)($1.21)($1.23)
Q4 20172($1.32)($1.19)($1.26)
(Data provided by Zacks Investment Research)


Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 89.22%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.00View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.00View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.00View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.00View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.35View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateHeadline logoALNY Crosses Above Average Analyst Target - July 21 at 5:23 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Lowered to "Hold" at Zacks Investment Research - July 17 at 4:04 PM logoZacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $22.22 Million - July 15 at 8:19 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from Analysts - July 14 at 6:44 PM logo-$1.20 Earnings Per Share Expected for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) This Quarter - July 13 at 2:16 PM logoAlnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth - July 12 at 9:19 PM logoAlnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation - July 11 at 9:59 PM logoAlnylam Buckles Down On A Belt Of Rare Diseases - Seeking Alpha - July 11 at 4:59 PM logoToday's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma - July 11 at 4:59 PM logoAlnylam (ALNY) Stock Down Despite Positive Hemophilia Data - July 11 at 4:59 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Cowen and Company - July 11 at 4:10 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Morgan Stanley - July 10 at 11:32 PM logoAlnylam And Sanofi Produce Monster Alternative In Hemophilia Market - Seeking Alpha - July 10 at 8:46 PM logoNeedham & Company LLC Reiterates "Buy" Rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - July 10 at 7:14 PM logoSilence Therapeutics Notes Alnylam Starts Phase III Fitusiran Trial - July 10 at 3:43 PM logoAlnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors - July 10 at 3:43 PM logoAlnylam Commences Phase III Study for Hemophilia Candidate - July 10 at 3:43 PM logoCould Alnylam Have An Edge On This Smaller Biotech In Rare Disease? - July 10 at 3:43 PM logoAlnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at Chardan Capital - July 10 at 3:04 PM logoAlnylam Pharma (ALNY), Sanofi (SNY) Initiate Phase 3 Program for Fitusiran for Hemophilia A and B - - July 8 at 5:03 AM logoAlnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why - Motley Fool - July 8 at 5:03 AM logoAlnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why - July 7 at 10:07 AM logoBiotechs Gained $1.7 Billion Last Week — Can They Keep Going? - July 5 at 4:26 PM logoBidaskClub Downgrades Alnylam Pharmaceuticals, Inc. (ALNY) to Buy - June 29 at 10:32 PM logo[$$] Alnylam Selloff Looks Like an Overreaction - June 28 at 3:57 PM logoCredit Suisse Group Raises Alnylam Pharmaceuticals, Inc. (ALNY) Price Target to $96.00 - June 27 at 9:14 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Given Buy Rating at Needham & Company LLC - June 27 at 8:06 AM logoAlnylam and Sanofi Genzyme to Present New Clinical Trial Results ... - Business Wire (press release) - June 27 at 4:31 AM logoAlnylam: Givosiran Shows Positive Clinical Results In Acute Hepatic Porphyrias - June 26 at 11:29 PM logoBRIEF-Alnylam Pharmaceuticals reports results for Givosiran - June 26 at 11:29 PM logoAlnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress - June 26 at 11:28 PM logoAlnylam Pharma (ALNY) Announced New Positive Clinical Results ... - - June 26 at 3:56 PM logoAlnylam priced at perfection - JPMorgan; shares off 5% - Seeking Alpha - June 26 at 3:56 PM logoAlnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias - June 26 at 3:56 PM logoQ2 2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. (ALNY) Increased by Analyst - June 26 at 7:10 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives New Coverage from Analysts at Jefferies Group LLC - June 22 at 11:02 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Piper Jaffray Companies - June 21 at 4:22 PM logo Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $21.26 Million - June 21 at 9:52 AM logoBRIEF-Alnylam CEO, John Maraganore, named BIO chair for 2017-2018 term - June 20 at 1:11 AM logoAlnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term - June 20 at 1:11 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from Brokerages - June 19 at 6:58 PM logoZacks: Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) to Post -$1.22 Earnings Per Share - June 19 at 2:06 PM logoBidaskClub Upgrades Alnylam Pharmaceuticals, Inc. (ALNY) to "Strong-Buy" - June 18 at 1:52 PM logoWhy is Alnylam's (ALNY) Stock Close to 100% this Year? - June 15 at 5:06 PM logoAlnylam Pharma (ALNY) Reports Expansion of Patent Portfolio with ... - - June 13 at 8:30 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Increased to Hold at ValuEngine - June 13 at 4:40 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Given a $110.00 Price Target at Chardan Capital - June 13 at 2:12 PM logoAlnylam Pharma (ALNY) Reports Expansion of Patent Portfolio with New Allowances from United States Patent & Trademark Office - June 12 at 4:32 PM logoAlnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office - June 12 at 4:32 PM logoReviewing Oramed Pharmaceuticals (ORMP) & Alnylam Pharmaceuticals (ALNY) - June 9 at 7:42 AM



Alnylam Pharmaceuticals (ALNY) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff